What is Turbine?
Turbine operates at the forefront of pharmaceutical innovation, offering a sophisticated virtual laboratory platform designed to simulate complex biological experiments. By leveraging advanced computational models and artificial intelligence, Turbine enables life science organizations to more effectively prioritize drug targets, design intricate combination therapies, and generate validated hypotheses. This technology is crucial for streamlining the drug discovery pipeline, reducing the time and cost associated with bringing new therapeutics to market.
How much funding has Turbine raised?
Turbine has raised a total of $61.7M across 4 funding rounds:
Other Financing Round
$3.4M
Other Financing Round
$6.8M
Series A
$26.5M
Series B
$25M
Other Financing Round (2019): $3.4M with participation from o2h Ventures, Atlantic Labs, Delin Ventures, Esther Dyson, and Vishal Gulati
Other Financing Round (2021): $6.9M led by o2h Ventures, XTX Ventures, Atlantic Labs, Accel, Boston Millenia Partners, and Delin Ventures
Series A (2023): $26.5M supported by MassMutual Ventures, Day One Capital, Accel, Delin Ventures, and Mercia Technologies
Series B (2026): $25M featuring Accel, Interactive Venture Partners, Beiersdorf, and Mercia Technologies
Key Investors in Turbine
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth. The firm focuses on supporting innovative companies and entrepreneurs.
Day One Capital
Day One Capital is an early-stage technology investor that manages privately financed funds aimed at supporting exceptional founders in Central Eastern Europe. They focus on seed stage ventures, particularly in the B2B software sector.
Delin Ventures
Delin Ventures is a mission-driven investor and company builder focused on transforming lives through innovations in life sciences and technology. They invest in and build cell therapy companies for scalability and sustainability.
What's next for Turbine?
With the recent influx of major strategic capital, Turbine is poised for an accelerated growth phase. The company is expected to further enhance its platform's capabilities, expand its market reach, and deepen its partnerships within the pharmaceutical and biotechnology sectors. This investment signals strong confidence in Turbine's technology and its potential to revolutionize drug discovery processes, positioning the company as a key player in the future of therapeutic development.
See full Turbine company page
